Executive SummaryAccording to Azoth Analytics research report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.The pri…
The ankylosing spondylitis market was valued at $5,140.94 million in 2020, and is projected to reach $8,110.59 million by 2030, registering a CAGR of 4.6%% from 2021 to 2030. Ankylosing spondylitis (AS) is a rare type of arthritis that causes pain and sti…
Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, and Pirfenidone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global idiopathic pulmonary fibrosis market was valued at $3,126.08 million in 2020, and is projected to reach $6,169.37 million by 2030, registering a CAGR of 7.0% from 2021 to 2030. Idiopathic pulmonary fibrosis is a chronic lung disease or a condit…
PET-CTスキャナー装置市場:タイプ別(据置型スキャナー、携帯型/移動型スキャナー)、サービスプロバイダー別(病院、診断センター、研究機関)、スライス数別(低スライススキャナー(<64 Slices), Medium Slice Scanner (64 Slices), and High Slice Scanner (>64 Slices))、アイソトープ/検出器タイプ(FDG、62Cu ATSM、18Fフッ化ナトリウム、FMISO、ガリウム、タリウム、その他)アプリケーション(腫瘍学、神経学、心臓学、その他)。世界の機会分析および産業予測、2021-2030年
The global PET-CT scanner device market was valued at $1,876.14 million in 2020, and is projected to reach $3,202.48 million by 2030, registering a CAGR of 5.5% from 2021 to 2030.
Positron emission tomography-computed tomography (PET-CT) is a medical anal…
The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.The prostate is a walnut-sized gland that surrounds the …
The global specialty PACS market was valued at $2,682.88 million in 2020, and is projected to reach $4,485.96 million by 2030, registering a CAGR of 5.5% from 2021 to 2030.PACS (picture archiving and communication system) is a medical imaging technology u…
Oncternal Therapeutics, Inc - Strategy, SWOT and Corporate Finance ReportSummaryOncternal Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure…
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance ReportSummaryAcorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, oper…
Kidney Cancer (Renal Cell Cancer) (Oncology) - Drugs in Development, 2021SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) – Drugs In Development, 2021, provides an overview of the…
Ovarian Cancer (Oncology) - Drugs in Development, 2021SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer – Drugs In Development, 2021, provides an overview of the Ovarian Cancer (Oncology) pipeline la…
Colon Cancer (Oncology) - Drugs in Development, 2021SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer – Drugs In Development, 2021, provides an overview of the Colon Cancer (Oncology) pipeline landscap…
Bile Duct Cancer (Cholangiocarcinoma) (Oncology) - Drugs in Development, 2021SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) – Drugs In Development, 2021, provides an overvie…
Medulloblastoma (Oncology) - Drugs in Development, 2021SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma – Drugs In Development, 2021, provides an overview of the Medulloblastoma (Oncology) pipeline…
Report Scope:Chronic disease management includes numerous drugs and medical device-based techniques used for the management of various chronic diseases. This report is an analytical business tool with the primary purpose of providing a thorough evaluation…